法匹拉韦抗新型冠状病毒的机制研究进 展  

Research Progress on the Potential Mechanism of Favipiravir Against SARS-CoV-2

作　　者：阿热依·巴哈提 王均琪 祝娜 白颖璐 曹靖宜 张明烁 张严 李志勇 黄秀兰[1] ARAY Baht;WANG Junqi;ZHU Na;BAI Yinglu;CAO Jingyi;ZHANG Mingshuo;ZHANG Yan;LI Zhiyong;HUANG Xiulan(College of Pharmacy,Minzu University of China,Beijing 100081,China;College of Life Environmentand Science,Minzu University of China,Beijing 100081,China;Institute of Traditional Chinese Medicine,Chinese Academy of Traditional Chinese Medicine,Beijing 100700,Chine)

机构地区：[1]中央民族大学药学院,北京100081 [2]中央民族大学生命环境与科学学院,北京100081 [3]中国中医科学院中药研究所,北京100700

出　　处：《医药导报》2022年第11期1651-1659,共9页Herald of Medicine

基　　金：中央民族大学自主科研项目(交叉学科研究专项)(2020MDJC04)。

摘　　要：新型冠状病毒肺炎(COVID-19)是一种由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)所致的传染病,自2019年末以来在全球迅速传播。当前科学界正进行前所未有的努力,研究该病毒感染的潜在机制并提出合理的临床应用药物,以降低COVID-19发病率。法匹拉韦(favipiravir)是一种RNA依赖性RNA聚合酶(RdRp)抑制剂,在中国被批准用于治疗COVID-19。该文概述法匹拉韦通过结合SARS-CoV-23种关键病毒酶RdRp、3-胰凝乳蛋白酶样半胱氨酸蛋白酶(3CLpro)和木瓜蛋白酶样蛋白酶(PLpro)抑制SARS-CoV-2的机制,并综述法匹拉韦与上述病毒蛋白酶的分子对接数据。Corona virus disease 2019(COVID-19),as an infectious disease caused by severe acute respiratory syndrome coronavirus type 2(SARS-CoV-2),spread rapidly across the world at the end of 2019.The rapid spread of COVID-19 has also prompted the scientific community to make unprecedented efforts to study the potential mechanism of viral infection and propose reasonable clinical applications to reduce the incidence of COVID-19.Favipiravir,an RNA-dependent RNA polymerase(RdRp)inhibitor,is approved in China for the treatment of COVID-19.This article outlines that favipiravir inhibits SARS-CoV-2 by binding to three key viral enzymes of SARS-CoV-2,RdRp,3-chymotrypsin-like protease(3CL_(pro)),and Papain-like-protease(PL_(pro)).And this paper reviewed the data of the molecular docking of favipiravir and the above-mentioned viral proteases of SARS-CoV-2.

关 键 词：法匹拉韦 新型冠状病毒肺炎 RNA依赖性RNA聚合酶 3-胰凝乳蛋白酶样半胱氨酸蛋白酶 木瓜蛋白酶样蛋白酶 

分 类 号：R978.7[医药卫生—药品] R511[医药卫生—药学]